Repligen Co. (NASDAQ:RGEN) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Repligen Co. (NASDAQ:RGEN) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $190.25.

A number of research analysts have weighed in on RGEN shares. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Wolfe Research started coverage on Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating for the company. StockNews.com raised Repligen from a “sell” rating to a “hold” rating in a research note on Friday. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. Finally, Benchmark reiterated a “hold” rating on shares of Repligen in a report on Monday, August 5th.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $142.58 on Friday. The firm has a market capitalization of $7.99 billion, a P/E ratio of -385.34, a P/E/G ratio of 3.87 and a beta of 0.96. The firm’s 50-day moving average price is $140.20 and its 200-day moving average price is $143.62. The company has a current ratio of 10.44, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. Repligen has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. During the same period in the prior year, the business earned $0.23 EPS. The firm’s revenue for the quarter was up 9.7% on a year-over-year basis. Equities research analysts anticipate that Repligen will post 1.52 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 1.20% of the company’s stock.

Institutional Investors Weigh In On Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Champlain Investment Partners LLC lifted its holdings in shares of Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Repligen by 21.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock valued at $172,749,000 after purchasing an additional 237,884 shares during the period. Conestoga Capital Advisors LLC grew its position in shares of Repligen by 26.7% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock valued at $119,363,000 after purchasing an additional 199,322 shares in the last quarter. Thrivent Financial for Lutherans increased its holdings in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after purchasing an additional 36,773 shares during the period. Finally, DF Dent & Co. Inc. raised its position in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after buying an additional 139,615 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.